ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer
1 clinical trials · Condition
◉ Watch ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer
| Record | Firm | Date |
|---|---|---|
| Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. (NCT04053322) | UNICANCER | 2019-08-26 |
Track ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.